POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
A phase I trial of plinabulinin combination with nivolumaband ipilimumabin patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Chemotherapy Induced Profound Neutropenia (PN) in Patients (pts) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim(Peg) Combination versus (vs) Peg Alone. Final Phase 3 Results from PROTECTIVE-2
(BPI-2358-106)
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Clinical Trial Testing Superiority of Combination Plinabulin and Pegfilgrastim vs Pegfilgrastim Alone in Patients with Breast Cancer Treated with High Febrile Neutropenia Risk Chemotherapy: Final Results of the Phase 3 Chemotherapy-Induced Neutropenia Prevention Trial (PROTECTIVE-2)
American Society of Hematology (ASH) Annual Meeting (2020)
12.2020
American Society of Hematology (ASH) Annual Meeting (2020)
PROTECTIVE-2 (BPI-2358-106): A CONFIRMATORY TRIAL TO DEMONSTRATE SUPERIORITY OF THE PLINABULIN + PEGFLIGASTRIM (PLIN/PEG) COMBINATION vs STANDARD OF CARE PEGFILGASTRIM FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NEUTROPENIA (CIN) IN BREAST CANCER PATIENTS
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Severe Neutropenia (Grade 4 Neutropenia) as a Population Based Predictor for Adverse Clinical Outcome of Chemotherapy Induced Neutropenia
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Impact of Adding Plinabulin to Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia on Patient Quality of Life (QoL)
PUBLICATIONS
Clinical Cancer Research (2010) 16:5892-5899
12.01.2010
Clinical Cancer Research (2010) 16:5892-5899
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Cancer Chemotherapy and Pharmacology
12.06.2019
Cancer Chemotherapy and Pharmacology
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
Chem
11.14.2019
Chem
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes